ERADICATION OF HELICOBACTER-PYLORI WITH LANSOPRAZOLE, AMOXICILLIN, AND PLAUNOTOL IN DUODENAL-ULCER PATIENTS

Helicobacter pylori eradication therapy combining amoxicillin (AMPC), plaunotol (PL), and a proton pump inhibitor (PPI) was examined as an a lternative to triple therapy, which has a high rate of side effects an d low patient compliance. Thirty-two H. pylori-positive patients (24 m en, 8 women) with duodenal ulcers were examined. The diagnosis of H. p ylori infection was made by the urease test on specimens biopsied from two sites in the stomach. Simultaneously, the IgG antibody against H. pylori was measured by the EIA method. The therapeutic regimen was la nsoprazole (LPZ) 30 mg q.d. (6 weeks) and AMPC 1,500 mg t.i.d. (2 week s) plus PL320 mg b.i.d. (6 weeks). The rate of ulcer healing was judge d endoscopically after 6 weeks. Cases that become urease-negative afte r the cessation of the therapy were defined as having achieved clearan ce, and those negative after 1 month as eradication. Within 6 weeks, 3 1 of 32 patients had healed ulcers. All patients were H. pylori antibo dy-positive before therapy. The clearance rate was 71.9% (23/32) and t he eradication rate was 45.8% (11/24), Adverse effects were observed o nly in one case. We conclude that combination therapy with LPZ, AMPC, and PL has a high therapeutic effect on ulcer healing and moderate eff ectiveness for eradication of H. pylori.